Shots:

• The P-II EMPOWER CSCC-1 study results involve assessing of Libtayo (cemiplimab-rwlc) in patients with LA & metastatic CSCC and will be presented at ASCO 2019
• The P-II EMPOWER CSCC-1 study results: median follow-up (9 & 17mos.); ORR (44% & 49%); CRR (13% & 17%); PRR (31% & 32%); DCR @≥16wks. (63% & 63%); mPFS with metastatic CSCC (18mos.)
• Libtayo is a mAb targeting PD-1- co-developed by Regeneron and Sanofi utilizing VelocImmune technology and has received FDA’s approval for patients with metastatic CSCC or LA CSCC who are not candidates for curative surgery or curative radiation in Sep’18

Ref: Sanofi | Image: Etoile